Compare CCG & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCG | NTRB |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | China | United States |
| Employees | 548 | 3 |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.5M | 54.1M |
| IPO Year | N/A | N/A |
| Metric | CCG | NTRB |
|---|---|---|
| Price | $0.78 | $3.87 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $350.00 | N/A |
| AVG Volume (30 Days) | ★ 66.6K | 12.4K |
| Earning Date | 03-30-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | $15.80 | $3,394.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $3.42 |
| 52 Week High | $1.54 | $11.68 |
| Indicator | CCG | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 42.00 |
| Support Level | $0.74 | $3.64 |
| Resistance Level | $0.81 | $4.50 |
| Average True Range (ATR) | 0.02 | 0.27 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 70.58 | 46.15 |
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services and other services in China.. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.